source
- Endeavor BioMedicines reports positive phase 2b results for Hedgehog inhibitor taladegib in IPFEndeavor BioMedicines announced that its Hedgehog pathway inhibitor, taladegib, produced encouraging results in a phase 2b study of patients with idiopathic pulmonary fibrosis (IPF). The trial, nam…
- Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…BioSpace · 12d agoNegative readoutNegative